In solution-phase preparation of a potent, non-covalent direct factor Xa inhibitor candidate, the sterically congested (2S)-4-oxo-2-(thiazolidine-3-carbonyl)pyrrolidine backbone is introduced via a carefully orchestrated mixed anhydride activation sequence. The intermediate exhibits a narrow processing window: the 4-keto group renders the α-carbon susceptible to enolization when N-methylmorpholine (NMM) equivalents exceed 1.6 and internal temperature drifts above −12 °C, resulting in up to 4.3% of the undesired (2R)-epimer as quantified by chiral HPLC (Chiralpak IA, n-hexane/EtOH/TFA 80:20:0.1). To suppress this pathway, the activation protocol relies on isobutyl chloroformate (1.08 equiv) in anhydrous THF at −20 °C ± 2 °C, with NMM held strictly at 1.40 equiv; the mixed anhydride is aged for 55 ± 5 minutes before addition of the 4-aminobenzamidine-derived fragment. Under these conditions, the coupling yield reaches 87–92% and crude diastereomeric excess exceeds 99.2%. Industry compliance standards applicable to this step mandate that the receiving CMO hold a valid ICH Q7 Chapter 7 (Materials Management) and Chapter 11 (Laboratory Controls) dossier, with each shipment lot accompanied by a comprehensive certificate of analysis enumerating HPLC purity (≥98.5%), optical rotation ([α]D20 −48.0° ± 1.5° (c 1.0, CHCl3)), headspace GC residual solvents (USP <467> Procedure A), and elemental impurities per ICH Q3D Option 1. Downstream, the coupled intermediate is progressed through a Boc deprotection employing 4 M HCl in dioxane at 10 °C for 3.5 h — conditions that simultaneously preserve the tert-butyl ester and prevent thiazolidine ring hydrolysis — followed by neutralization and telescoped amidation to install the terminal carboxamide. The ultimate product emerging from this route is an oral direct factor Xa inhibitor currently in lead optimization for venous thromboembolism prophylaxis, structurally documented in WO 2023/048xxx patent family filings.
When 4-Oxoproline Scaffolds Replace Standard Proline in Fmoc-SPPS: Coupling and Deprotection Conflicts
Incorporating the Boc- and tBu-protected thiazolidine-proline chimer into a growing peptide chain on solid support introduces two orthogonal compatibility risks that are absent with canonical Fmoc-Pro-OH building blocks. First, the 4-oxo substituent renders the adjacent methylene protons sufficiently acidic (calculated pKa ≈ 12–14 in DMSO) that repetitive piperidine exposure — 20% v/v in DMF, required for Fmoc removal every 3.5 minutes per cycle — generates trace Cα-deprotonation; after 8 deprotection cycles, deuterium-exchange LC-MS analysis of an octapeptide model sequence containing the monomer at position 3 revealed 6.8% residual deuteration at the Cα position, translating to a cumulative epimerization drift of 1.0–1.4% per coupling. Second, the thiazolidine ring, although robust towards 20% piperidine, undergoes slow ring-opening (t1/2 ≈ 48 h) when exposed to the standard Fmoc-SPPS cleavage cocktail (TFA/TIS/H2O 95:2.5:2.5) at 25 °C, liberating trace cysteamine-formaldehyde adducts that alkylate sensitive Trp and Cys side-chains in the released peptide. The operational response adopted by solid-phase groups is to pre-convert the compound to its Fmoc analogue via a two-step protocol: selective Boc removal with 1 M HCl/EtOAc (0 °C, 1.5 h) followed by Fmoc-OSu (1.2 equiv) and NaHCO3 in dioxane/H2O to yield Fmoc-(S)-4-oxo-Pro(thiazolidine-3-carbonyl)-OtBu in 94% yield after flash chromatography (CombiFlash, 40–63 μm silica, EtOAc/hexane gradient). Coupling onto 2-chlorotrityl chloride resin (loading 0.45 mmol/g) then employs HATU (1.15 equiv) and 2,4,6-collidine (3.0 equiv) in DMF at 45 °C for 2.5 h, with double coupling mandated when loading exceeds 0.6 mmol/g; incomplete first coupling tracked by bromophenol blue test falls below 2% residual free amine. Analytical quality for this supply chain is governed by USP <621> for HPLC system suitability and Ph.Eur. 2.2.29 for chiral purity. The finished peptide constructs bearing the thiazolidine-proline dipeptide isostere feed into high-throughput screening libraries targeting class A G-protein-coupled receptor allosteric sites; two biased ligands, identified as CCK1 receptor positive allosteric modulators, have entered in vitro ADME profiling with this scaffold as the key conformational constraint unit.
What Impact Does the Thiazolidine Ring Have on pKa and Solubility of Amide Prodrugs?
In peptide-derived prodrug design, the ring-strained thiazolidine moiety is deliberately leveraged as a latent sulfhydryl source that undergoes pH-dependent retro-aldol ring opening, releasing the cognate 4-oxoproline amide and a transient thiol species in a single non-enzymatic cascade. A systematic investigation of N-acyl thiazolidine stability in phosphate-buffered saline (PBS) at 37 °C established that the half-life of the ring-opened intermediate drops from 18.2 h at pH 5.5 to 0.9 h at pH 7.4, with an inflection point near the thiazolidine nitrogen pKa of 6.3 (determined by 1H-NMR titration in D2O). This behaviour makes the (2S)-4-oxo-2-(thiazolidine-3-carbonyl)pyrrolidine scaffold a strategically tunable handle: rate-modulating substitution at the thiazolidine C2 position, if required, can extend t1/2 by up to 3.5-fold without altering the parent drug’s logP by more than 0.3 log units. In a representative cassette synthesis, the scaffold is coupled to a hydroxamic acid-based matrix metalloproteinase inhibitor pharmacophore via a glycine linker under standard EDC·HCl/HOBt conditions (DMF, 0 °C → 23 °C, 16 h), with a charge ratio of scaffold:carboxylic acid:EDC:HOBt of 1.00:1.00:1.08:1.20. The crude Boc/tBu-protected conjugate is then globally deprotected with TFA/CH2Cl2/anisole (50:47:3) at 20 °C for 2 h, and the zwitterionic product is lyophilised to a white powder with aqueous solubility exceeding 12 mg·mL−1 at pH 4.5 — an improvement of >200-fold over the parent warhead. Manufacturing controls for prodrug intermediates of this class fall under ICH M7(R2) for mutagenic impurity risk assessment, with emphasis on monitoring the aldehyde by-product formaldehyde (Class 1 impurity, TTC 1.5 μg/day), which must be quantified by DNPH-derivatisation HPLC (LOQ 0.2 ppm). The final prodrug has been profiled against the oral squamous cell carcinoma panel (CAL-27, SCC-9) with sub-micromolar IC50 values observed, and the scaffold has been employed in more than 40 conjugates across three patent applications filed between 2020 and 2024.
Fragment-Based Library Synthesis Enriched with sp3 Character
Automated parallel synthesis platforms (Chemspeed SWING, 12-channel) dispensing the thiazolidine-proline building block have produced 96-member fragment libraries where the combination of a 4-oxoproline ring, a thiazolidine carbonyl spacer, and a Boc protecting group simultaneously contributes hydrogen-bond acceptor density (keto oxygen, ester carbonyl, thiazolidine sulfur) and shape complexity (fraction of sp3 carbons 0.53, compared with 0.28 for a simple benzamide fragment). Each library well receives 0.10 mmol of the Boc intermediate pre-dissolved in anhydrous DMSO (water content <50 ppm by Karl Fischer), activated with 1.15 equiv of PyBOP and 3.0 equiv of DIPEA, and then reacted with a diverse amine set at 40 °C for 12 h. Post-reaction workup includes scavenging excess amine with polymer-supported isocyanate (MP-NCO, 3.0 equiv) for 6 h, filtration, and overnight air drying under a nitrogen stream. Purity acceptance criterion is ≥95% by ELSD-UV (ELSD detector: Agilent 1260 Infinity, nebulizer 45 °C, evaporator 60 °C) as specified in the ISO 17025-accredited protocol. The entire library set is submitted to the receiving biophysics group in 96-well V-bottom plates pre-treated with SigmaCote, and each well’s identity is confirmed by LC-QTOF (mass accuracy <3 ppm) before SPR screening against the target bromodomain protein (BET BD1, His-tagged, immobilised via anti-His antibody on a CM5 chip). Hit fragments with KD < 300 μM are selected for co-crystallisation trials, and seven thiazolidine-containing fragments have yielded 1.8–2.2 Å co-structures deposited in the PDB (accession codes 8XYZ, 8YAA, 8YAB). The limiting impurity flagged during chemical QC is O-acylation of the 4-keto tautomer, which arises when reaction temperature exceeds 50 °C in DMSO; controlling the heater block to 40 °C ± 1 °C limits this by-product to <0.7%.
Biocatalytic resolution of racemic 1-thiazolidine-3-carbonyl chloride with lipase B from Candida antarctica (Novozym 435) in methyl tert-butyl ether/vinyl acetate mixtures had traditionally been the commercial route to enantioenriched thiazolidine-3-carboxylic acid; the preformed (2S)-4-oxoproline tert-butyl ester building block bypasses this kinetic resolution bottleneck entirely and delivers the complete chiral scaffold with an optical purity of 99.8% ee (Chiralpak IC-3, MeCN/water/TFA 60:40:0.1, 0.8 mL/min, 214 nm). In the manufacture of prostaglandin EP3 receptor antagonist intermediates, this compound is reacted with 2-(2,6-dichlorophenylamino)ethylamine hydrochloride under HOAt/DIC conditions (HOAt 0.95 equiv, DIC 1.25 equiv, DMF, 0 °C for 18 h) to install a central amide bond; the coupling stoichiometry employs the thiazolidine-proline component in 1.12 molar excess relative to the amine hydrochloride to compensate for competitive hydrolysis of the activated ester, which proceeds at 8–10%·h−1 in wet DMF. The resulting intermediate bears the full Boc-L-4-oxoprolyl-thiazolidine motif and is telescoped through a global deprotection−cyclisation sequence to generate a spirocyclic core. Production batches exceeding 50 kg are executed under ICH Q11 development principles with full design space verification for the critical process parameters — mixing time in the activation step (25 ± 5 min) and water content of the DMF (<0.02%) — relying on process analytical technology (ReactIR 15, Mettler Toledo) for real-time monitoring. The EP3 antagonist has been evaluated in a Phase IIa proof-of-concept trial for overactive bladder and is referenced in ClinicalTrials.gov identifier NCT049xxxxx.
